AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03624933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
Study NCT03527082 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire of 20 items evaluating attitudes and perception of mesh use in gynaecological surgery. Questionnaire will take 10 minutes to complete. For non-English speaking patients a translator will be sought, where feasible to help women complete the questionnaire.~Participation will be entirely voluntary and also the questionnaire will be piloted to ensure that questions asked are clear and concise. Questionnaire is anonymised and does not contain patient identifying information thereby eliminating breach of confidentiality.
Study NCT01762215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PatientsLikeMe.com
Description: PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
Study NCT03111485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Description: Capsule 250 mg / 50 mg taken at bedtime
Study NCT03111485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Capsule taken at bedtime
Study NCT01345747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal tube (VBM Medizintechnik, Sulz, Germany)
Description: laryngeal tube suction number 3 and 4
Study NCT04533087 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02967705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain management group
Description: Chronic pain patients participate in a peer group. They are provided information about chronic pain self-management based on biopsychosocial framework.
Study NCT02221349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium oxalate
Description: Professionally applied (liquid) and self applied (gel)
Study NCT02221349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sodium fluoride paste
Description: Toothpaste used by subject
Study NCT02221349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Stannous fluoride paste
Description: Toothpaste used by subject
Study NCT03906383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: Brief reversible restriction of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
Study NCT02582606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular meal pattern
Description: a 14-day period of eating 6 meal per day
Study NCT02582606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Irregular meal pattern
Description: a 14-day period of eating between 3 and 9 meal per day
Study NCT02529982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Study NCT02529982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01931787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study NCT02595671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Super Coach
Description: Receive Digital Super Coach during 12 weeks
Study NCT02595671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional face to face PA & dietitian
Description: Receive 7 face-to-face contacts (dietary and physical activity advice)
Study NCT02595671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Super Coach + minimal coaching
Description: Receive 3 face-to-face contacts (dietary and physical activity advice)
Study NCT02595671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting Group
Description: Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
Study NCT02742753 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
Study NCT03880032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Intervention for Anxiety
Description: Happy Mother Healthy Baby (HMHB) is a CBT-based psychosocial intervention for expectant women experiencing anxiety during their pregnancy. Strategies such as empathetic listening, thought challenging, behavior activation, problem management, take-home exercises, and family involvement are employed by HMHB.
Study NCT03462420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy program
Description: The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
Study NCT03462420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy program
Description: The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
Study NCT04967781 — intervention group
Intervention type: BEHAVIORAL
Intervention: autoimmunity
Description: autoimmunity is characterized as self attacking from self immune system, which may involve in the severe progression of COVID-19.
Study NCT03961217 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy as part of cancer treatment
Study NCT03947450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Skin Fibroblasts
Description: The site or whole stump will be injected with autologous fibroblasts
Study NCT03947450 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The site or whole stump will be injected medium only without autologous skin fibroblasts
Study NCT02715336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulation induction with hCG and Lupron (GnRH agonist)
Description: Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
Study NCT00938717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide or Matching Placebo
Description: Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
Study NCT00938717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linaclotide or Matching Placebo
Description: Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
Study NCT01898897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural catheter insertion
Description: A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
Study NCT01898897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot assisted laparoscopic urogenital surgery
Description: The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
Study NCT01898897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robot assisted laparoscopic urogenital surgery
Description: The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 1)
Description: Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test (study 1)
Description: The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 2)
Description: Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
Study NCT03093753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test (study 2)
Description: The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 3)
Description: Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
Study NCT03093753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test (study 3)
Description: The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 4)
Description: Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to
Study NCT03093753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test (study 4)
Description: The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 5)
Description: Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test (study 5)
Description: The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 6)
Description: Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test (study 6)
Description: High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 7)
Description: Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
Study NCT03093753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test (study 7)
Description: High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
Study NCT01535495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol XL 120mg by mouth once daily
Study NCT00078325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg/day
Description: Armodafinil 250 mg once daily in the morning
Study NCT00078325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/day
Description: Armodafinil 150 mg once daily in the morning
Study NCT00078325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets once daily in the morning
Study NCT03054922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: IV infusion of 0.9% NaCl throughout surgery.
Study NCT03054922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: IV infusion of lactated ringer throughout surgery.
Study NCT03054922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normosol-R Inj
Description: IV infusion of Normosol throughout surgery.
Study NCT00786565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced Akreos Adapt in one operated eye.
Description: Cataract surgery to implant the assigned IOL according to randomized schedule.
Study NCT00786565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Akreos Adapt in fellow operated eye.
Description: Cataract surgery to implant the assigned IOL according to randomized schedule.
Study NCT00959998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered Acupressure
Study NCT00959998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered Acupressure
Study NCT01699542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WallFlex Esophageal RX Fully Covered Stent
Description: Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
Study NCT01699542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal Bougie Dilator Per Investigator preference
Description: Commercially available Esophageal Bougie Dilator Per Investigator preference
Study NCT03632590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate
Description: 450 mg of Magnesium Citrate per day (6 capsules per day) for 24 weeks
Study NCT03632590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 450 mg of Magnesium Sulfate per day (6 capsules per day) for 24 weeks
Study NCT03632590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide
Description: 450 mg of Magnesium Oxide per day (6 capsules per day) for 24 weeks
Study NCT03632590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will contain starch (Amylum solani) for 24 weeks
Study NCT05513625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir
Description: oral administration
Study NCT05513625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESO and pritelivir
Description: oral administration
Study NCT02047253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
Study NCT02047253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered prior to administration of Study drug
Study NCT02047253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Administered orally twice daily
Study NCT02693522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Subcutaneous injection
Study NCT02693522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eutropin
Description: Subcutaneous injection
Study NCT03805750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/THC
Description: Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
Study NCT03805750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matched Placebo
Study NCT01037660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1 gram per day
Study NCT01034592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 2.5 mg/wk up to 5 mg 3x/wk
Study NCT01987960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, tablets, orally
Study NCT01987960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 1 to 3 mg/day, once daily dose, tablets, orally
Study NCT00317720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose.
Study NCT00317720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
Study NCT02241382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal Electrocardioversion
Description: Cardioversion by internal shock application via the implanted ICD
Study NCT02241382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Electrocardioversion
Description: Cardioversion by external shock application via a cardioverter/defibrillator.
Study NCT03745833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mindfulness
Description: Participating patients will be provided with a VR headset (pre-programmed with mindfulness content) after lunch for 15 minutes with supervision while on strict bedrest. The headset will be collected following the intervention. Patients are currently provided with a post-meal survey following all meals as part of the standard of care, and will complete the survey following the lunchtime intervention.
Study NCT00946504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
Study NCT00946504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
Study NCT03583983 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized Health Recommendations
Description: Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).
Study NCT03583983 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Generic Health Recommendations
Description: Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
Study NCT01045798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin acetate
Description: 70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
Study NCT01045798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
Study NCT02372565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook and text Message
Description: Culturally-relevant physical activity promotion program
Study NCT02372565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Print-based Intervention
Description: Non-culturally relevant physical activity promotion program
Study NCT02536313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Study NCT02536313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT04357873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab; vorinostat
Description: Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression
Study NCT02720770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norditropine simplex